Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics and clinicopathological variables for the study population and samples included in PCR validation

From: Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study

Characteristic NOWAC pilot study
Study population PCR analyses
Cases N (%) Controls N (%) Cases N (%) Controls N (%)
Study subjects 108 (100) 44 (100) 40 (100) 20 (100)
Age (years)
 ≤ 50 7 (6.5) 1 (2.3) 1 (2.5) 1 (5.0)
 > 50 101 (93.5) 43 (97.7) 39 (97.5) 19 (95.0)
Tumor grade
 1 34 (31.5) 7 (17.5)
 2 42 (38.9) 17 (42.5)
 3 28 (25.9) 16 (40.0)
 Unknown 4 (3.7)   0 (0)  
Tumor size (mm)
 0–10 23 (21.3) 2 (5.0)
 10–20 50 (46.3) 24 (60.0)
 > 20 34 (31.5) 14 (35.0)
 Unknown 1 (0.9)   0 (0)  
Lymph node status
 N0 73 (67.6) 30 (75.0)
 N+ 34 (31.5) 10 (25.0)
 Unknown 1 (0.9) 0 (0)
Hormone receptor status
 ER/PR positive 81 (75.0) 23 (57.5)
 ER/PR negative 27 (25.0) 17 (42.5)
 Unknown 0 (0) 0 (0)
HER2 receptor status
 HER2 positive 20 (18.5) 15 (37.5)
 HER2 negative 86 (79.6) 25 (62.5)
 Unknown 2 (1.9) 0 (0)
Molecular subtype
 Luminal A 58 (53.7) 12 (30.0)
 Luminal B 22 (20.4) 11 (27.5)
 HER2 positive 9 (8.3) 7 (17.5)
 Triple-negative 16 (14.8) 10 (25.0)
 Unknown 3 (2.8)   0 (0)  
Histological type
 Infiltrating carcinoma NST 92 (85.2) 35 (87.5)
 Lobular carcinoma 10 (9.3) 3 (7.5)
 Tubular 3 (2.8) 0 (0)
 Other 3 (2.8) 2 (5.0)